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Abstract: Problem statement: Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and its cognate 
targets, the Matrix Metalloproteinases (MMPs), were differentially expressed in human brain samples 
with  or  without  HIV-1  infection  or  HIV-1  Encephalitis  (HIVE).  Approach:  A  through  literature 
review demonstrated that cell culture models of Central Nervous System (CNS) cell types had been 
used to illustrate the intricate temporal patterns of TIMP-1/MMP expression, regulated by a variety of 
inflammatory cytokines. Results: As MMPs and TIMP-1 can significantly altered the extracellular 
environment  and  cell  signaling,  the  differential  regulation  of  TIMP-1/MMP  expression  in 
neuroinflammation  can  impact  neuronal  function  and  survival  in  disease  conditions.  TIMP-1  pro-
survival effects had been demonstrated in a variety of cell types including CNS neurons, protecting 
cells from a wide range of stress and insults. TIMP-1, also known to interact with non-MMP targets, 
altered cell behavior. In this review, we discussed the possibility that the upregulation of TIMP-1 by 
glia in acute neuroinflammation may be a neuroprotective response. Conclusion: It will be important 
to  delineate  the  effects  of  TIMP-1  on  neurons  and  identify  receptors  and  downstream  signaling 
pathways,  in  order  to  evaluate  TIMP-1  as  a  therapeutic  strategy  for  neuroinflammatory  and 
neurodegenerative diseases. 
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INTRODUCTION 
 
In  vivo  expression  of  TIMP-1  and  MMPs  in 
HAD/HIVE  disease:  In  advanced  Human 
Immunodeficiency  Virus  type  1  (HIV-1)  infection, 
virus  and  activated  immune  cells  perturb  the  Central 
Nervous  System  (CNS),  leading  to  HIV-1-Associated 
Dementia  (HAD,  lately  termed  HAND,  HIV-1-
associated  neurocognitive  disorders),  with  devastating 
symptoms  such  as  cognitive  changes  and  motor 
dysfunction.  Neuropathology  examination  of  patient 
samples usually reveal nodules of infiltrating, activated 
Mononuclear Phagocytes (MP) and reactive gliosis in 
their vicinity
[1], a condition termed HIV-1 Encephalitis 
(HIVE). Analysis of patient brain and Cerebral Spinal 
Fluid  (CSF)  samples  revealed  a  high  upregulation  of 
Matrix  Metalloproteinases  (MMP)-9  and  MMP-2 
mRNA  in  HIVE  samples  than  in  HIV-1  seropositive 
patients without HAD (designated as HIV+) or healthy 
controls
[2].  Further  immunohistochemical  studies 
comparing these three categories demonstrated that, in 
patients with severe HIVE, activated MP (positive for 
CD68 and HLA-DR) infected with HIV-1 (positive for 
HIV-1p24) in microglial nodules were the main source 
of MMP-2
[2]. MMP-9 was detected on most activated 
MP,  even  those  that  were  negative  for  HIV-1p24  in 
HIVE  samples  and  HIV+  samples
[2].  MMP-2  protein 
was significantly upregulated in both HIVE and HIV+ 
brain  samples  compared  to  seronegative  controls 
without neurological disease
[3]. 
  Expression of MMPs and TIMP-1 is known to be 
regulated  by  inflammatory  cytokines
[4],  which  are  in 
turn  differentially  expressed  in  neuroinflammation. 
Compared  to  healthy  controls,  both  HIV+  and  HIVE 
brain  samples  exhibited  significantly  higher  mRNA 
levels for IL-1beta
[3] and higher protein levels of TGF-Am. J. Infect. Dis., 5 (4): 307-313, 2009 
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beta2,  while  TGF-beta2  mRNA  was  significantly 
increased  only  in  HIVE  samples
[5].  TIMP-1  protein 
levels, however, were significantly lower in both HIVE 
and HIV+ patients as compared to healthy controls
[3]. 
Of  possible  interest,  TIMP-1  protein  levels  were 
significantly  lower  in  the  white  matter  than  in  basal 
ganglia  or  cerebellum  of  a  HIVE  patient
[3].  It  was 
sufficiently obvious that inflammatory cytokines were 
differentially  expressed  in  HAD/HIVE  as 
communication  signals  between  immune  cells  and 
responding cell types. What, then, were the roles of the 
differentially expressed MMPs and TIMP-1? Were they 
beneficial  to  neuronal  function,  or  detrimental  in  the 
degrading  extracellular  environment?  The  general 
functions of TIMP-1 and MMPs are briefly reviewed 
below to suggest their possible roles in HAD/HIVE. 
 
General review of TIMPs and MMPs: Extracellular 
Matrix  (ECM)  homeostasis  and  remodeling  are 
accomplished  through  activities  of  Matrix 
Metalloproteinases  (MMPs),  a  large  family  of  zinc-
dependent  proteases.  The  homeostasis  of  ECM  is 
important  for  normal  function  of  many  organs  and 
remodeling  by  MMPs  is  essential  in  diverse 
physiological  processes  including  angiogenesis  and 
wound healing
[7]. MMPs are classified according to the 
type  of  substrates:  MMP-2  and  -9  are  the  prominent 
gelatinases,  MMP-1  is  the  most  well-studied  of  the 
collagenases  and  other  types  of  MMPs  include 
stromelysins (e.g., MMP-3), matrilysins (e.g., MMP-7) 
and Membrane-Type (MT)-MMPs which are attached 
to  the  outer  surface  of  cell  membranes  rather  than 
soluble  in  the  extracellular  milieu
[5].  MMPs  are  also 
responsible  for  processing  cell-surface  signaling 
receptors  and  their  ligands,  such  as  the  apoptosis-
inducing  Fas  Ligand  (FasL)
[7].  Furthermore,  aberrant 
MMP expression or activity has been observed in many 
pathological  conditions,  including  tumor  metastasis
[8]. 
It  follows  that  proper  regulation  of  MMP  activity  is 
crucial for an extracellular environment permissive to 
normal cell functioning. 
  In  addition  to  controls  in  gene  expression  and 
protein secretion, MMP activity is further regulated by 
activation  in  the  extracellular  environment  from 
proenzymes  to  active  MMPs  and  sequestration  and 
inhibition  by  their  endogenous  inhibitors,  the  four 
members  of  tissue  inhibitor  of  metalloproteinases
[6,9]. 
These members, termed TIMP-1 through -4, are small 
extracellular  proteins  which  reversibly  bind  to  the 
active site of MMPs and inhibit their interaction with 
substrates
[9]. Each TIMP can inhibit a wide spectrum of 
MMPs.  TIMPs  may  also  regulate  MMPs  by 
mechanisms  other  than  direct  inhibition.  TIMP-2,  for 
example,  with MT1-MMP can activate proMMP-2 to 
its  active  form
[9,10].  As  MMPs  are  involved  in  many 
extracellular functions; TIMPs, as their inhibitors, have 
been found to affect  many cellular  functions that are 
dependent on the ECM or other extracellular signals. 
TIMP-1  is  of  particular  interest  in  disease  processes 
because it is expressed at a non-detectable or very low 
level  in  most  tissues  in  homeostasis,  but  is  highly 
inducible by various stimuli, especially inflammation. 
TIMP-1  regulates,  among  many  other  pathways,  the 
JAK,  PI3  kinase,  Bcl-2,  FAK  and  MAP  kinase 
pathways  in  a  variety  of  cell  types,  leading  to  cell 
survival
[11-14]  and  differentiation  in  the  case  of  B 
cells
[15]. Intricate cell-signaling pathways aside, it is just 
as likely that TIMP-1 can protect neurons by inhibiting 
the  overly-high  activity  levels  of  MMPs  in 
neuroinflammation, thereby maintaining the integrity of 
the  Blood-Brain  Barrier  (BBB)  and  decreasing 
trafficking immune cells, the cytokines of which may 
be detrimental to neurons. 
 
Glial  expression  of  TIMP-1  and  MMP  in  HAD 
conditions:  Primary  human  microglia  in  culture 
exhibited detectable expression of MMP-1 and -3 and 
higher  expression  levels  of  MMP-2  and  -9
[2].  CD40 
ligand (CD40L), an inflammatory signal, increased all 
of  these  MMPs  in  cultured  microglia.  Moreover, 
monocytes  isolated  from  healthy  donors  exhibited  a 
high increase in MMP-2 and -9 expression when cells 
differentiated  into  Monocyte-Derived  Macrophages 
(MDM)  in  culture.  While  these  results  may  be 
applicable  to  all  neuroinflammatory  conditions, 
further studies revealed that HIV-1 infection impacted 
MP production of MMPs. Infection with CNS isolates 
HIV-1DJV,  HIV-1JR-FL,  or  Cerebrospinal  Fluid  (CSF) 
HIV-1  isolates  HIV-1SF162  and  HIV-1MSCSF  all 
downregulated MDM expression of MMP-9
[2]. Among 
the HIV-1 strains tested, only the CNS isolate HIV-1YU-
2 had no effect on MDM expression of MMP-9. More 
importantly, inflammatory stimuli such as CD40L still 
upregulated MMP-9 expression in MDM infected with 
the tested HIV-1 strains, except in MDM infected with 
HIV-1YU-2. Thus, MMPs from MP could have important 
roles  in  the  neuroinflammatory  disease  of  HAD. 
Meanwhile, stimulation with CD40L and differentiation 
also increased MDM secretion of TIMP-1, thus TIMP-1 
expression from MP  was concurrently increased  with 
MMPs
[2]. 
  Although MP initiate the inflammatory cascade in 
HAD  neuroinflammation,  contribution  into  the 
MMP/TIMP  axis  by  the  numerically  and  spatially 
prevalent astroglia should not be overlooked. Astrocyte 
expression  of  MMP-2  was  increased  after  6  days  in Am. J. Infect. Dis., 5 (4): 307-313, 2009 
 
309 
culture without any cytokine stimulation
[3] and MMP-1 
after  14  days
[16].  When  stimulated  with  IL-1beta, 
astrocyte  expression  of  MMP-2  peaked  between 6-
20  days
[3]  and  MMP-1  level rose significantly after 
20  days
[16].  MMP-7  production  by  astrocytes,  on  the 
other  hand,  was  drastically  increased  by  IL-1beta 
stimulation  after  24  h,  but  decreased  over  time  to  no 
significant difference to unstimulated cells by day 14
[16]. 
As for within the first 24 h of stimulation, IL-1beta did 
not  increase  astrocyte  secretion  of  MMP-2  unless 
simultaneously  stimulated  with  TGF-beta1  or  TGF-
beta2,  while  the  two  TGF-beta  isoforms  significantly 
downregulated  the  IL-1beta-stimulated  increase  of 
proMMP-1
[5].  Moreover,  IL-1beta  stimulation 
significantly  upregulated  astrocyte  secretion  of  TGF-
beta2 after 7 days and TGF-beta1 after 14 days
[5]. These 
studies  demonstrated  the  intricate  network  of 
inflammatory  cytokine  signaling  and  feedback  to 
astrocytes  and  the  inherent  differences  in  expression 
patterns  of  different  MMPs  in  astrocytes.  In  general, 
astrocyte  production  of  MMPs  is  upregulated  by  IL-
1beta stimulation and increased over time. 
  With astrocytes composing the majority of cells in 
the CNS, such drastic changes in their MMP expression 
can be balanced only by their expression of the TIMPs. 
Primary  human  astrocytes  significantly  upregulated 
TIMP-1 expression in acute stimulation with IL-1beta 
within 24 h
[3,16]. Furthermore, astrocyte production of 
TIMP-1 was also modulated by the presence of HIV-1 
virions  and  products  of  HIV-1-infected  MP
[3]. 
Astrocytes  treated  with  supernatant  from  control  MP 
and  IL-1beta-stimulated  MP  supernatant  exhibited 
comparable TIMP-1 production. However, there was a 
significant increase in TIMP-1 production in astrocytes 
treated with HIV-1-infected MP supernatant and further 
increase  in  astrocytes  treated  with  supernatant  from 
HIV-1-infected,  IL-1beta-stimulated  MP.  Astrocyte 
TIMP-1  was  also  differentially  regulated  in  the 
presence of HIV-1 viral particles. While treatment with 
HIV-1ADA particles did not alter astrocyte secretion of 
TIMP-1,  presence  of  HIV-1SF162  caused  a  slight 
increase and production in astrocytes treated with HIV-
1JR-FL or HIV-1DJV was significantly increased
[3]. Taken 
together, these studies revealed that TIMP-1 expression 
was  differentially  regulated  in  astrocytes  by 
inflammatory stimuli and HAD conditions. 
  In summary, many of the MMPs under study were 
upregulated by inflammatory cytokines over a course of 
days,  while  TIMP-1  was  upregulated  by  an  acute 
stimulation  of  approximately  24  h.  Under  IL-1beta 
stimulation, a robust  increase of TIMP-1  mRNA and 
protein  level  observed  in  the  first  24  h  was  virtually 
obliterated by day 7 of stimulation
[4,15]. Since astrocytes 
in  vivo  in  HIVE  and  HIV+  patients  had  chronic 
exposure to IL-1beta as the disease progressed, these in 
vitro results explained the consistent drop in TIMP-1 
mRNA and protein levels in the CNS of these patients 
compared to healthy controls. 
  Further studies into the control mechanism of this 
downregulation  of  TIMP-1  in  chronic 
neuroinflammation  were  also  conducted  in  primary 
human  astrocytes.  In  acute  stimulation,  IL-1beta 
considerably  upregulated  TIMP-1  mRNA  and  protein 
secretion in astrocytes, but both TGF-beta1 and TGF-
beta2 could knock down this increase, although not to 
baseline  level  in  acute  stimulation
[4].  Studies  using 
reporter  constructs  of  the  TIMP-1  promoter 
demonstrated that following IL-1beta stimulation, TGF-
beta1  and  TGF-beta2  could  decrease  the  promoter 
activity and/or mRNA stability of TIMP-1
[15]. Thus, in 
the  context  of  HAD  neuroinflammation,  IL-1beta 
upregulates astrocyte TIMP-1 expression only in a very 
short, initial time frame, while also inducing expression 
of the two forms of TGF-beta. TGF-beta1 and -beta2 
then  begin  to  downregulate  TIMP-1  expression. 
Meanwhile,  expressions  of  MMP-2  and  MMP-9  are 
increased.  In  summary,  over  the  time  course  of 
neuroinflammation,  the  MMP/TIMP  balance  is 
considerably shifted in favor of the MMPs. 
 
Neuroprotective  capabilities  of  TIMP-1  against  a 
variety of insults: The differential regulation of MMPs 
and  TIMP-1  by  glia  in  neuroinflammation  serves 
multiple  purposes.  First  of  all,  the  changes  in  the 
MMP/TIMP  axis  alter  the  homeostatic  state  of  the 
ECM.  Increased  MMP  expression  can  facilitate  MP 
infiltration  into  the  CNS  in  HAD  and  this  can  be 
countered by TIMP-1. A parallel was demonstrated in 
an experimental autoimmune encephalomyelitis (EAE) 
mouse model for multiple sclerosis, another important 
and  well-studied  neuroinflammatory  degenerative 
disease  with  immune  cell  infiltration  into  the  CNS. 
Compared to “wild-type” EAE mice, TIMP-1 knockout 
mice  had  more severe pathology after EAE induction, 
evaluated in terms of EAE disease score, numbers and 
activation  states  of  infiltrating  T  cells  and  MP  and 
demyelination
[17].  Logically,  in  both  HAD  and  EAE, 
TIMP-1  can  protect  the  basement  membrane  on  the 
vasculature, thereby decreasing the number of infiltrating 
and  activated  immune  cells  that  can  exacerbate 
inflammation, which is detrimental to neurons. 
  MMP/TIMP effect on neurons, however,  may be 
far  beyond  the  maintenance  of  the  ECM.  In  a  study 
with  kainate-induced  seizure,  a  mouse  model  for 
epilepsy and acute excitotoxicity, induction or addition 
of the gelatinase MMP-9 was correlated with neuronal Am. J. Infect. Dis., 5 (4): 307-313, 2009 
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death after kainate injection
[13]. This  was  not entirely 
due to MMP activity on the ECM, since in the same 
study, MMP-2, another major gelatinase, had no effect 
on  neuron  death  after  kainate
[18].  A  subsequent  study 
observed  that  TIMP-1  expression  was  induced  as  an 
immediate-early gene after kainate treatment
[19]. This, 
however,  was  again  beyond  inhibiting  the  neurotoxic 
MMP-9,  since,  paradoxically,  wild-type  mice  able  to 
express  TIMP-1  had  more  neuron  death  in  specific 
regions of the hippocampus than in TIMP-1 knockout 
mice  after  kainate-induced  seizure
[19].  Moreover, 
expression  of  MMP-2,  MMP-9  and  gelatinolytic 
activity were elevated after kainate in wild-type mice, 
but  not  in  TIMP-1  knockout  mice,  suggesting  that 
TIMP-1 may help activate the gelatinases, or feed-back 
upregulating  expression  of  these  gelatinases
[19]. 
Behaviorally,  TIMP-1  knockout  mice  had  normal 
susceptibility to kainate-induced seizure, but exhibited 
deficits in learning and memory
[19]. While this may not 
have a bearing on the survival of neurons per se in CNS 
pathology,  the  presence  and  activity  of  TIMP-1  may 
improve or preserve cognitive performance of patients 
with neurodegenerative diseases. 
  An  intricate  study  revealed  that  TIMP-1 
neuroprotection may have nothing to do with inhibition 
of MMP activity, but is specific to an intact TIMP-1 
protein and specific to the type of insult to neurons
[20]. 
In this study of acute glutamate excitotoxicity, neurons 
transfected with TIMP-1 in an adenoviral vector were 
protected from glutamate toxicity. Neurons with control 
transfection  of  beta-galactosidase  were  not  protected, 
showing that the effect was not due to the transfection 
procedure. More importantly, neurons transfected with 
TIMP-3,  or  treated  with  broad-spectrum  MMP 
inhibitors BB94 or MMP inhibitor (MMPI)-1 were not 
protected  from  glutamate  toxicity,  demonstrating  that 
neuroprotection  from  glutamate  excitotoxicity  in  this 
model  was  TIMP-1-specific  and  inhibition  of  MMPs 
was  not  sufficient  for  neuroprotection.  To  further 
elucidate the neuroprotective mechanism, Tan et al.
[20] 
used  N-TIMP-1-T2G,  a  non-MMP-interacting  mutant 
of TIMP-1, with the threonine at the second amino acid 
position  mutated  to  glycine,  expressed  as  the  N-
terminal  domain  of  TIMP-1
[21,22].  Neither  N-TIMP-1-
T2G added to the culture nor transfection with a non-
secretable  form  of  TIMP-1  provided  neuroprotection 
against glutamate toxicity, demonstrating that TIMP-1 
neuroprotection  was  mediated  by  an  intact  TIMP-1 
protein in an extracellular position
[20]. Calcium imaging 
studies  revealed  that  the  calcium  influx  into  neurons 
after glutamate treatment was significantly decreased in 
neurons  treated  with  TIMP-1,  implicating  TIMP-1  in 
the  modulation  of  calcium-permeable  glutamate 
receptors
[20].  Of  interest,  TIMP-1  did  not  protect 
neurons from chemical ischemia induced by potassium 
cyanide,  indicating  that  TIMP-1  neuroprotection  was 
specific to the type of insults on neurons
[20]. 
  TIMP-1-mediated neuroprotection was thus seen in 
diverse in vivo and in vitro models, including the EAE 
mouse  model  and  TIMP-1  knockout  mouse  model. 
While  the  mechanism  of  neuronal  injury  in  the  EAE 
model  was  inflammatory,  glutamate  excitoxicity  in 
vitro and injuries in kainate-seizure mouse model were 
dependent  on  neuronal  activity.  Based  on  this  wide 
variety of injury mechanisms in these different models, 
TIMP-1  was  implicated  in  different  neuroprotection 
pathways.  TIMP-1  was  linked  to  preservation  of  the 
ECM  through  inhibition  of  MMPs
[17],  non-inhibiting 
regulation  of  MMPs
[19]  and  the  completely  non-
classical  modulation  of  ionotropic  glutamate 
receptors
[20]. The studies with potassium cyanide
[20] and 
TIMP-1  knockout
[19]  also  indicate  that  TIMP-1-
mediated  neuroprotection  may  not  be  evident  in  all 
types  of  neuronal  injuries.  Thus,  TIMP-1  has 
differential  effects  on  neurons  depending  on  the 
mechanism of the specific insult and tissue context. 
 
A  novel  TIMP-1  receptor:  CD63:  As  discussed 
earlier,  three  independent  studies  indicate  TIMP-1 
neuroprotection  to  be  mediated  through  mechanisms 
dependent  on  either  MMPs  or  neuron-specific 
ionotropic  glutamate  receptors.  Many  other  studies 
have  demonstrated  MMP-independent  TIMP-1  pro-
survival  effects,  however,  in  cell  types  that  do  not 
express ionotropic glutamate receptors, such as Burkitt’s 
lymphoma B cell lines, mouse bone marrow stromal cell 
line  MBA-1  and  human  breast  epithelial  cell  line 
MCF10A
[11,13,14].  Such  results  strongly  indicate  that 
TIMP-1 may signal through a variety of “receptors” in 
different  cell  types.  Conversely,  some  “TIMP-1 
receptors”  other  than  MMPs  or  ionotropic  glutamate 
receptors  may  also  be  active  in  TIMP-1-mediated 
neuroprotection  in  other  contexts  such  as  HIVE 
neuroinflammatory environment. 
  In  search  for  a  novel  TIMP-1  receptor,  CD63,  a 
tetraspanin  (transmembrane-4  superfamily;  TM4SF) 
was  identified  by  yeast  two-hybrid  screening  as 
interacting  with  the  C-terminal,  non-MMP-inhibiting 
domain of TIMP-1
[23]. Further experiments revealed cell-
surface  co-localization  of  TIMP-1,  CD63  and  beta1 
integrins
[23]. The tetraspanins are known for promiscuous 
protein-protein  associations  on  the  cell  membrane, 
forming functional microdomains with other tetraspanins 
and  integrins
[24,25].  Similarly,  the  beta1  subunit  of 
integrins is known to associate with a variety of integrin 
alpha  subunits,  forming  integrin  dimers  with  diverseAm. J. Infect. Dis., 5 (4): 307-313, 2009 
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Fig. 1: TIMP-1 neuroprotective mechanisms are disengaged in chronic inflammation 
 
functions  including  modulation  of  cell  growth  and 
survival
[26]. In accordance with the wide variety of cell 
signaling  associated  with  CD63  and  beta1  integrins, 
experiments  found  CD63  necessary  for  TIMP-1 
mediated ERK activation and inhibition of apoptosis 
in  MCF10A  cells
[23].  Beyond  regulation  of  cell 
survival, overexpression of TIMP-1 in these cells also 
caused loss of cell polarization behavior necessary for 
formation  of  normal  acini  structure,  a  phenotype 
restored  by  downregulation  of  CD63
[23].  This  study 
demonstrated not only that TIMP-1 could promote cell 
survival through integrins and a tetraspanin instead of 
MMPs, but also opened up a wide field of research for 
intracellular pathways signaling TIMP-1 non-classical 
effects,  as  all  pathways  associated  with  CD63  and 
beta1  integrin  could  potentially  be  modulated  by 
TIMP-1. 
 
CONCLUSION 
 
  In  this  review,  we  discussed  the  differential 
regulation of MMP/TIMP-1 expression in disease and 
TIMP-1-mediated  neuroprotection.  TIMP-1  pro-
survival and differentiation-inducing effects have been 
demonstrated in a wide variety of cell types and disease 
models.  Several  divergent  protein  families  including 
MMPs, tetraspanins and integrins have been indicated 
as  functional  “TIMP-1  receptors”.  Both  classical  and 
non-classical  pathways  mediating  TIMP-1 
neuroprotection  have  been  shown  in  different  neural 
injury models. A complex alteration in the MMP/TIMP 
axis has also been demonstrated in neuroinflammatory 
diseases  including  HAD.  Much  remains  to  be 
elucidated,  however,  as  to  the  precise  and  divergent 
roles  that  TIMP-1  plays  in  HAD  neurodegeneration. 
Here  we  include  a  schematic  summarizing  TIMP-1 
regulation  and  activities  in  HAD  and  neuroprotective 
mechanisms,  including  CD63  as  a  potential  TIMP-1 
receptor in neurons (Fig. 1). 
  Based on results discussed above, TIMP-1 in HAD 
can potentially decrease infiltration of HIV-1-infected 
and activated immune cells, reduce neuroinflammation, 
confer neuroprotection and improve cognitive function 
of  patients.  A  marked  downregulation  of  TIMP-1  in 
chronic  neuroinflammation  may  contribute  to  the 
exacerbated neurodegeneration in HAD. Thus, studies 
into  TIMP-1  neuroprotective  mechanisms  as  may  be 
found in HAD conditions are important for both basic 
science  advancement  and  development  of  novel 
therapeutic intervention strategies. 
  In  HIV-1-infection,  activated/infected  phagocyte 
crosses  the  blood-brain  barrier  and  enters  the  CNS. 
Cytokine communication and HIV particles from the 
MP  activate  microglia,  which  contribute  to  the 
inflammatory cascade and activate astroglia. Activated 
astrocytes alter their expression patterns of TIMP-1, 
MMP-2 and -9. TIMP-1 can moderate MMP activity 
level. TIMP-1 can also prevent excitotoxicity through 
ionotropic  glutamate  receptors
[20].  Further,  TIMP-1 
can potentially interact with neuronal beta1 integrins 
and CD63 and activate survival pathways
[23]. Overall, 
upregulation of TIMP-1 may be beneficial to the HIV-
1-infected CNS. As chronic inflammatory stimulation 
downregulates  astrocyte  expression  of  TIMP-1, 
TIMP-1  neuroprotection  is  lost  in  HAD/HIVE 
patients. Am. J. Infect. Dis., 5 (4): 307-313, 2009 
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